SecBot SecBot
6-K ·Filed Sep 8, 2026

BWAY

Brainsway Ltd.
NEUTRAL
Impact 4/10
Horizonmonths Processed2mo ago SEC0001171843-26-005912
Notable filing: 6-K
Actionable Insight • Neutral

This is a scientific update with no near-term commercial or regulatory catalyst. Monitor for any subsequent announcement of a larger controlled trial in Alzheimer's, which would be the next meaningful de-risking event. The existing 20-F (April 2026) showed strong revenue growth of 27% to $52.2M, that fundamental trajectory is the primary driver, not this pilot data.

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$14.16
T+0 close · Sep 8, 2026 · via day close
Latest settled
−16.03%
T+20 · $11.89 · next T+60 in 15d
Vs SPY
−18.00%
α at T+20
Latest observation
−22.75%
T+48 · FF3 residual α
  1. T+0 · Sep 8 $14.16entry
  2. T+1 · 2mo ago +1.77%α +2.23% · $14.41
  3. T+5 · 2mo ago −3.74%α −3.08% · $13.63
  4. T+20 · 6w ago −16.03%α −18.00% · $11.89
  5. T+49 · todayOpen
  6. T+60 · in 15d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BrainsWay announced publication of a pilot study (n=12) in the Journal of Geriatric Psychiatry and Neurology showing Deep TMS achieved an 83.3% response rate and 50% remission rate for depressive symptoms in patients with comorbid MDD and early-stage Alzheimer's disease, alongside measurable neurophysiological changes. This is an early-stage, hypothesis-generating result in a new indication (Alzheimer's) for which Deep TMS is not FDA-cleared, requiring additional controlled trials before any commercial pathway. The filing is a routine scientific update with no financial data, no regulatory submission, and no change to the company's existing three FDA-cleared indications, making it a modest positive signal for the platform's optionality but not a near-term catalyst.

Key Facts

  • Pilot study (n=12) published in peer-reviewed Journal of Geriatric Psychiatry and Neurology
  • 83.3% response rate and 50% remission rate for depressive symptoms in patients with MDD and early-stage Alzheimer's
  • Deep TMS is NOT FDA-cleared for Alzheimer's disease; additional controlled research required
  • Study used H1 and H7 coils; observed QEEG changes in delta power and alpha coherence
  • No financial figures, guidance, or regulatory milestones reported in this filing

Financial Impact

No financial impact reported; pilot study is early-stage research with no revenue or cost implications disclosed

Risk Factors

  • Pilot study has very small sample size (n=12) and no control arm, limiting generalizability
  • Deep TMS is not FDA-cleared for Alzheimer's; path to clearance requires large, expensive pivotal trials with uncertain outcomes

Market Snapshot

Exchange
OTC
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001171843-26-005912
Document: f6k_090626.htm0001171843-26-005912
Document: 0001171843-26-005912-index-headers.html0001171843-26-005912
Document: 0001171843-26-005912-index.html0001171843-26-005912
Document: 0001171843-26-005912.txt0001171843-26-005912

Track record

24 reports on BWAY

Performance horizon

6 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +27.55% at T+60 after the Mar 4, 2026 report. 8 of 11 went positive at some point.

Filters
  1. Nov 10, 20266d ago 6-K Bullish 6/10 No price data
  2. Nov 10, 20266d ago 6-K Neutral 5/10 Entry $10.67 Now $9.39 −12.00% settles Dec 9
  3. Nov 2, 202614d ago 6-K Neutral 3/10 Entry $11.09 Now $9.39 −15.33% settles Dec 1
  4. Nov 2, 202614d ago Press Release Neutral 3/10 Entry $11.09 Now $9.39 −15.33% settles Dec 1
  5. Oct 26, 202621d ago 6-K Neutral 3/10 Entry $11.21 Now $9.39 −16.24% settles Nov 23
  6. Oct 21, 202626d ago 6-K Neutral 3/10 Entry $11.44 Now $9.39 −17.92% settles Nov 19
  7. Oct 19, 202628d ago 6-K Neutral 3/10 Entry $11.99 to $9.39 Now $9.39 −21.68% ▼ −21.68% −18.22% vs SPY
  8. Oct 19, 202628d ago Press Release Neutral 4/10 Entry $11.99 to $9.39 Now $9.39 −21.68% ▼ −21.68% −18.22% vs SPY
  9. Oct 13, 20264w ago 6-K Neutral 4/10 Entry $11.92 to $10.67 Now $9.39 −21.22% ▼ −10.49% −6.88% vs SPY
  10. Sep 8, 20269w ago 6-K Neutral 4/10 Viewing Entry $14.16 to $11.89 Now $9.39 −33.69% ▼ −16.03% −18.00% vs SPY
Showing 10 of 24

US Market Status

Market Closed · Opens Wed (11h 17m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 9, 2026